All In Biotech

Drug Trial Radar · NCT03409107

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)

A 28-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center, Study in Recombinant Human Erythropoietin (rhEPO) naïve Non-dialysis Participants With Anemia Associated With Chronic Kidney Disease to Evaluate the Efficacy, Safety and Effects on Quality of Life of Daprodustat Compared to Placebo

Last checked: Nov 19, 2026Latest source record: Apr 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 614 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

614

Actual

Start

Mar 5, 2018

Primary completion

Oct 7, 2020

Study completion Oct 7, 2020

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jan 24, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this multi-center study in non-dialysis participants with anemia associated with CKD is to evaluate safety, efficacy and quality of life of daprodustat compared to placebo.

Conditions

  • Anaemia

Interventions

  • Daprodustat (GSK1278863)Drug

    Daprodustat will be available as 9 millimeter (mm) or 7 mm film-coated tablets. Daprodustat will be administered once daily via oral route and can be taken without regard to food.

  • PlaceboDrug

    Daprodustat matching placebo will be available as 9 mm or 7 mm film coated tablets. Placebo will be administered once daily via oral route and can be taken without regard to food.

  • Iron therapyDrug

    Iron therapy will be administered if ferritin is \<50 Nano gram per milliliter and/or TSAT is \<15 percent.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change in Hemoglobin From Baseline and Over the Evaluation Period (Mean Over Week 24 and 28)Time frame: Baseline (Day 1) and Week 24 to Week 28

Locations

168 sites in 14 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Homewood, Alabama

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Downey, California

  • GSK Investigational Site

    Fresno, California

  • GSK Investigational Site

    Lynwood, California

  • GSK Investigational Site

    Northridge, California

  • GSK Investigational Site

    Northridge, California

  • GSK Investigational Site

    Riverside, California

  • GSK Investigational Site

    Salinas, California

  • GSK Investigational Site

    Santa Ana, California

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    Hartford, Connecticut

  • GSK Investigational Site

    Middlebury, Connecticut

  • GSK Investigational Site

    Coral Springs, Florida

  • GSK Investigational Site

    Hollywood, Florida

  • GSK Investigational Site

    Kissimmee, Florida

  • GSK Investigational Site

    Lauderdale Lakes, Florida

  • GSK Investigational Site

    Pembroke Pines, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Adairsville, Georgia

  • GSK Investigational Site

    Macon, Georgia

  • GSK Investigational Site

    Macon, Georgia

  • GSK Investigational Site

    Statesboro, Georgia

  • GSK Investigational Site

    Indianapolis, Indiana

  • GSK Investigational Site

    Overland Park, Kansas

  • GSK Investigational Site

    Buckley, Michigan

  • GSK Investigational Site

    Detroit, Michigan

  • GSK Investigational Site

    Saint Clair Shores, Michigan

  • GSK Investigational Site

    Brookhaven, Mississippi

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Rochester, New Hampshire

  • GSK Investigational Site

    Asheville, North Carolina

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Durham, North Carolina

  • GSK Investigational Site

    Midwest City, Oklahoma

  • GSK Investigational Site

    Oklahoma City, Oklahoma

  • GSK Investigational Site

    Beaver, Pennsylvania

  • GSK Investigational Site

    Duncansville, Pennsylvania

  • GSK Investigational Site

    Scottdale, Pennsylvania

  • GSK Investigational Site

    Smithfield, Pennsylvania

Showing 40 of 168 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.